Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

6.950 +0.150 (+2.21%)
Streaming Delayed Price Updated: 1:29 PM EDT, Aug 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
Galmed Pharmaceuticals (GLMD) stock is gaining on Friday after the company announced an investment agreement with OnKai. 
Via InvestorPlace
Why is Nanobiotix (NBTX) Stock Up 107% Today?
Nanobiotix (NBTX) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3. 
Via InvestorPlace
Why Carvana Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning! 
Via InvestorPlace
Why Are Nanobiotix Shares Plummeting Today?
 
Via Benzinga
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
Company agreed to term sheet as of May 3, 2023 
From Nanobiotix S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Earnings Scheduled For April 24, 2023
Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million. 
Via Benzinga
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
 
Via Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3 
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.